New drug cocktail aims to shrink colorectal tumors

NCT ID NCT06722183

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs—futibatinib (a daily pill) and tislelizumab (an IV immunotherapy)—in adults with advanced colorectal cancer. The goal is to see if the combo can shrink tumors and to identify biomarkers that predict response. About 33 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Futibatinib (a targeted cancer pill) combined with tislelizumab (an immunotherapy drug given by IV)
What this could lead to
If successful, this could point toward a new treatment option for colorectal cancer that combines targeted therapy with immunotherapy to shrink tumors.
What could go wrong
This is an early phase 2 trial with only 33 participants, so results may not apply to all patients. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Charité Campus Virchow Klinikum (CVK)

    NOT_YET_RECRUITING

    Berlin, Germany

  • Hope Hamburg

    RECRUITING

    Hamburg, Germany

  • Kliniken Essen-Mitte

    RECRUITING

    Essen, Germany

  • Klinikum München rechts der Isar

    RECRUITING

    München, Germany

  • Klinikum St. Marien Amberg

    NOT_YET_RECRUITING

    Amberg, Germany

  • Krankenhaus Nordwest

    RECRUITING

    Frankfurt am Main, 60488, Germany

  • Leopoldina Krankenhaus Schweinfurt

    RECRUITING

    Schweinfurt, Germany

  • MVZ für Hämatologie und Onkologie Ravensburg GmbH

    NOT_YET_RECRUITING

    Ravensburg, 88212, Germany

  • Universitätsklinikum Düsseldorf

    RECRUITING

    Düsseldorf, Germany

  • Universitätsmedizin Mainz

    NOT_YET_RECRUITING

    Mainz, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.